Key facts
- XCath’s last known valuation is $62.0M (Jan 2022).
- It has raised $92.0M; the latest was Later Stage VC ($30.0M) in Mar 2026.
- Notable investors include CE-Ventures, Crescent Enterprises, Frederic Moll.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for XCath
- ·The full record, as it builds
Funding rounds
No funding rounds for XCath are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About XCath
Developer of advanced endovascular robotics and steerable guidewires designed to enhance precision in navigating the vascular system. The company platform offers tools for minimally invasive treatment of complex vascular conditions, enabling doctors to improve clinical outcomes, safer procedures, and faster recovery times.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2017
- Employees
- 50
- Website
- xcath.com/
- Ownership
- Privately Held (backing)
XCath doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in XCath shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on XCath in its N-PORT filings yet. We sweep new filings monthly.